Immuron submits Coffee Microcaps Conference presentation##

PUBT · 1d ago
Immuron submits Coffee Microcaps Conference presentation##
  • Immuron published an investor presentation tied to CEO Steven Lydeamore’s Coffee Microcaps Conference slot on Sept. 22, 2026.
  • Slides outline Travelan, an oral passive immunotherapy positioned to reduce the risk of travelers’ diarrhea caused by pathogenic bacteria.
  • Pipeline summary highlights IMM-529 for recurrent C. difficile infection as an adjunct to antibiotics, targeting toxin B, spores, surface proteins.
  • Presentation also covers ProIBS distribution in Australia and New Zealand, describing it as a medical device for IBS symptoms.
  • Links cited: https://www.immuron.com.au/ | https://www.travelan.com


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuron Limited published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-101907), on September 22, 2026, and is solely responsible for the information contained therein.